Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Meta Expands AI Training With Employee Activity Tracking Tools 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
EMERYVILLE, Calif., March 04, 2016 -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2015 after the market close, and will host a corporate update conference call and webcast on Thursday, March 10th at 4:30 PM Eastern Time.
| Thursday, March 10th @ 4:30 PM Eastern Time/1:30 PM Pacific Time | |
| Toll Free: | 888-337-8198 |
| International: | 719-325-2308 |
| Conference ID: | 5464024 |
| Webcast: | http://public.viavid.com/index.php?id=118497 |
| Replays, available through March 24, 2016: | |
| Domestic: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 5464024 |
About Zogenix
Zogenix, Inc. (NASDAQ:ZGNX) is an innovative pharmaceutical company committed to providing unique therapeutic solutions for people living with rare and burdensome disease conditions. Our focused strategy centers on advancing late-stage, high-value products for CNS disorders that will significantly improve outcomes for patients and physicians.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
